TY - JOUR
T1 - Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations
AU - Moser, Sarah Sharman
AU - Mazursky, Orr Friedman
AU - Shalev, Hadas
AU - Apter, Lior
AU - Chodick, Gabriel
AU - Siegelmann-Danieli, Nava
N1 - Publisher Copyright:
© 2023 Pfizer Pharmaceuticals Israel Ltd.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Aim: To describe treatment journey and clinical outcomes after palbociclib initiation in HR+/HER2- breast cancer patients across multiple lines. Materials & methods: Adult patients (n = 559) were identified in a population-based study between January 2018 and June 2020. Results: Median follow-up time was 41.2 months. The starting dose was 125 mg for more than 85% of patients, and a third had dose reduction. Median time on treatment was 30.5 months for palbociclib + aromatase inhibitors for patients that received first-line treatment after metastatic diagnosis, and 12.6 months for palbociclib + fulvestrant across multiple lines, and longer for patients that had a dose reduction during treatment. At 48 months, 59.3 and 27.3% of patients were still alive, respectively. Subsequent lines resulted in median time on treatment of 4.4-7.7 months in both groups. Conclusion: Time on treatment for palbociclib was comparable to data from clinical trials, and follow-up allowed us to examine subsequent treatment after initial treatment failure. Dose reduction was common in the real-world setting and did not adversely affect efficacy.
AB - Aim: To describe treatment journey and clinical outcomes after palbociclib initiation in HR+/HER2- breast cancer patients across multiple lines. Materials & methods: Adult patients (n = 559) were identified in a population-based study between January 2018 and June 2020. Results: Median follow-up time was 41.2 months. The starting dose was 125 mg for more than 85% of patients, and a third had dose reduction. Median time on treatment was 30.5 months for palbociclib + aromatase inhibitors for patients that received first-line treatment after metastatic diagnosis, and 12.6 months for palbociclib + fulvestrant across multiple lines, and longer for patients that had a dose reduction during treatment. At 48 months, 59.3 and 27.3% of patients were still alive, respectively. Subsequent lines resulted in median time on treatment of 4.4-7.7 months in both groups. Conclusion: Time on treatment for palbociclib was comparable to data from clinical trials, and follow-up allowed us to examine subsequent treatment after initial treatment failure. Dose reduction was common in the real-world setting and did not adversely affect efficacy.
KW - CDK4/6 inhibitors
KW - HR+/HER2- breast cancer
KW - observational study
KW - palbociclib
UR - http://www.scopus.com/inward/record.url?scp=85168222443&partnerID=8YFLogxK
U2 - 10.2217/fon-2023-0176
DO - 10.2217/fon-2023-0176
M3 - Article
C2 - 37529919
AN - SCOPUS:85168222443
SN - 1479-6694
VL - 19
SP - 1473
EP - 1483
JO - Future Oncology
JF - Future Oncology
IS - 21
ER -